Glycan targeting nanoparticle for photodynamic immunotherapy of melanoma.
10.1016/j.apsb.2022.08.009
- Author:
Yonghyun CHOI
1
;
Wooic SON
2
;
Youngpin HAN
2
;
Jayoung CHAE
1
;
Chul-Su YANG
2
;
Jonghoon CHOI
1
Author Information
1. School of Integrative Engineering, Chung-Ang University, Seoul 06974, Republic of Korea.
2. Department of Molecular & Life Science, Hanyang University, Ansan 15588, Republic of Korea.
- Publication Type:Journal Article
- Keywords:
Glycan;
Immune checkpoint;
Immunotherapy;
Lectin;
Macrophages;
Melanoma cancer;
Phagocytosis;
Photothermal nanoparticles
- From:
Acta Pharmaceutica Sinica B
2023;13(5):1903-1918
- CountryChina
- Language:English
-
Abstract:
Interaction between tumour cells and macrophages enables cancer cells to evade immune detection and clearance by interfering with macrophage phagocytosis. The anti-phagocytic signals regulated by anti-phagocytic proteins are termed "don't eat me" signals; these signals include sialic acid-binding immunoglobulin-type lectin-10 (Siglec-10) and the recently revealed CD24 immune checkpoint (ICP). In this study, we demonstrate that targeting a specific glycan on CD24 exhibits the potential to inhibit ICP. Sambucus nigra agglutinin (SNA), a sialic acid-binding lectin, was employed to block CD24 and to enhance phagocytosis in melanoma tumours. In addition, we prepared SNA-conjugated hollow gold-iron oxide nanoparticles for photothermal therapy of tumours. Our findings show that the combination treatment of SNA-conjugated photothermal nanoparticles and near-infrared exposure successfully augments tumour cell phagocytosis both in vitro and in vivo models.
